

RealRate

PHARMACEUTICAL 2018

Intra-Cellular Therapies Inc. Rank 14 of 342









PHARMACEUTICAL 2018





Intra-Cellular Therapies Inc. Rank 14 of 342

The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 234% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	469,215
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,210
Liabilities, Non-Current	0
Other Assets	1,134
Other Compr. Net Income	-482
Other Expenses	-1,061
Other Liabilities	2,840
Other Net Income	4,006
Other Revenues	246
Property and Equipment	1,137
Research and Development	79,419
Selling, General and Administrative Expense	23,667

Output Variable	Value in 1000 USD
Assets	471,487
Liabilities	17,050
Expenses	102,025
Revenues	246
Stockholders Equity	454,437
Net Income	-97,773
Comprehensive Net Income	-98,014
Economic Capital Ratio	280%

